UPDATE: Citadel Securities Initates Coverage on Dendreon

Citadel Securities has published a report on Dendreon DNDN initiating coverage of the biotech company. In the report, Citadel Securities wrote, "We expect competitor data from Johnson & Johnson's oral prostate cancer drug ZYTIGA to be available during 2012, with an interim look scheduled for 4Q11. Importantly, ZYTIGA oral formulation is a more convenient method for patients than PROVENGE's intravenous method." Citadel Securities rated Dendreon a Neutral with a price target of $10.00. Dendreon closed Friday at $12.56.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst RatingsBiotechnologycitadel securitiesDendreonHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!